July 30, 2026 Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer
July 30, 2026 New Clinical Research Presented at NUTRITION 2026 Shows Superbrewed Food’s Postbiotic Cultured Protein Matches Whey in Muscle-Building Response
